Azitra (AZTR) Amortizatization of Intangibles (2022 - 2026)
Azitra's (AZTR) quarterly Amortizatization of Intangibles came in at $78961.0 in Q1 2026, down 5.28% YoY from $83360.0 in Q1 2025, and up 1.11% on a QoQ basis from $78094.0 in Q4 2025.
Azitra (AZTR) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Amortizatization of Intangibles data on file, last reported at $78961.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 5.28% year-over-year to $78961.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $310676.0 (down 2.28% YoY) and the FY2025 annual result came in at $315075.0, down 0.62% from the prior year.
- Amortizatization of Intangibles grew to $78961.0 in Q1 2026, from $78094.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $274197.0 in Q4 2022 to a low of -$135026.0 in Q3 2022.
- A 5-year average of $76410.0 and a median of $78094.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- The widest YoY moves for Amortizatization of Intangibles: up 159.19% in 2023, down 72.2% in 2023.
- Tracing AZTR's Amortizatization of Intangibles over 5 years: stood at $274197.0 in 2022, then sank by 72.2% to $76238.0 in 2023, then rose by 8.23% to $82510.0 in 2024, then decreased by 5.35% to $78094.0 in 2025, then grew by 1.11% to $78961.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $78961.0 (Q1 2026), $78094.0 (Q4 2025), and $77235.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - | 74,769.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 74,769.00 |
| Jun 30, 2026 | 74,769.00 |
| Mar 31, 2026 | 78,961.00 |
| Mar 31, 2026 | 78,961.00 |
| Dec 31, 2025 | 78,094.00 |
| Dec 31, 2025 | 78,094.00 |
| Sep 30, 2025 | 77,235.00 |
| Sep 30, 2025 | 77,235.00 |
| Jun 30, 2025 | 76,386.00 |
| Jun 30, 2025 | 76,386.00 |
| Mar 31, 2025 | 83,360.00 |
| Mar 31, 2025 | 83,360.00 |
| Dec 31, 2024 | 82,510.00 |
| Dec 31, 2024 | 82,510.00 |
| Sep 30, 2024 | 70,636.00 |
| Sep 30, 2024 | 70,636.00 |
| Jun 30, 2024 | 81,434.00 |
| Jun 30, 2024 | 81,434.00 |
| Mar 31, 2024 | 82,467.00 |
| Mar 31, 2024 | 82,467.00 |